10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

10x Genomics (NASDAQ:TXG) issued its quarterly earnings results on Wednesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08), Zacks reports. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. 10x Genomics updated its FY 2025 guidance to EPS.

10x Genomics Stock Down 4.7 %

Shares of NASDAQ TXG traded down $0.57 during trading on Thursday, hitting $11.43. 1,739,655 shares of the company traded hands, compared to its average volume of 2,300,600. The firm has a market capitalization of $1.38 billion, a P/E ratio of -7.70 and a beta of 1.85. The company has a 50-day moving average price of $14.82 and a 200-day moving average price of $17.47. 10x Genomics has a 1 year low of $10.80 and a 1 year high of $51.22.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TXG shares. Stifel Nicolaus decreased their price target on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Morgan Stanley lowered their target price on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $25.00 to $12.00 in a research report on Thursday. Finally, Barclays lowered their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $21.21.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.